MediciNova Reports Third Quarter 2012 Results and Update on MN-221 … – NASDAQ

MediciNova Reports Third Quarter 2012 Results and Update on MN-221
NASDAQ
The decrease in research and development expenses was mainly due to a decrease in spending on MN-221 due to the completion of the MN-221-CL-007 trial in patients with acute exacerbations of asthma, partially offset by an increase in spending on our
MediciNova Says Considering Cost, Timing and Design of Future Trials; FDA Benzinga

all 8 news articles »

View full post on asthma – Google News

MediciNova Receives a Notice of European Patent Allowance for Treating … – NASDAQ

MediciNova Receives a Notice of European Patent Allowance for Treating
NASDAQ
MediciNova's pipeline includes six clinical-stage compounds for the treatment of acute exacerbations of asthma, chronic obstructive pulmonary disease exacerbations, multiple sclerosis and other neurologic conditions, asthma, interstitial cystitis
MediciNova Receives Notice of European Patent Allowance for Treating Benzinga

all 3 news articles »

View full post on asthma – Google News

MediciNova Announces Positive Preliminary Results From a Multi-Day, Repeat … – NASDAQ

MediciNova Announces Positive Preliminary Results From a Multi-Day, Repeat
NASDAQ
"There is a significant unmet medical need for an IV agent like MN-221 for asthma and COPD patients who are admitted to the ER due to a severe episode that is unresponsive to standard therapy," said Kazuko Matsuda, M.D., Ph.D., M.P.H, Chief Medical

and more »

View full post on asthma – Google News

MediciNova Enters Into a $20 Million Common Stock Purchase Agreement With … – NASDAQ

MediciNova Enters Into a $20 Million Common Stock Purchase Agreement With
NASDAQ
MediciNova will use the net proceeds from any sales of its stock to advance MediciNova's development activities for its lead programs, MN-221 (bedoradrine sulfate) in development for the treatment of acute asthma and chronic obstructive pulmonary

and more »

View full post on asthma – Google News

MediciNova Reports Results of a Phase 2b Clinical Trial of MN-221 in Asthma … – FierceBiotech

MediciNova Reports Results of a Phase 2b Clinical Trial of MN-221 in Asthma
FierceBiotech
MediciNova intends to design pivotal trial(s) that will include technological and operational improvements and further controls for medications that are not typically used in the treatment of acute exacerbations of asthma and were over-represented in
MediciNova Reports Results Of A Phase 2b Trial Of MN-221 In Asthma ExacerbationsNASDAQ

all 28 news articles »

View full post on asthma – Google News

MediciNova shares crash after lead asthma drug fails IIb trial – FierceBiotech

MediciNova shares crash after lead asthma drug fails IIb trial
FierceBiotech
MediciNova's ($MNOV) shares crashed after the San Diego-based biotech said its Phase IIb study of an acute asthma drug failed to hit the primary endpoint. And while the CEO tried to put the data in context, offering reasons for optimism for a planned
MediciNova asthma drug fails trial; shares crashMSN Money
MediciNova Reports Results of a Phase 2b Clinical Trial of MN-221 in Asthma MarketWatch (press release)

all 28 news articles »

View full post on asthma – Google News

MediciNova asthma drug fails trial; shares crash – Reuters

MediciNova asthma drug fails trial; shares crash
Reuters
(Reuters) – Biopharmaceutical company MediciNova Inc said its experimental asthma drug failed to meet the main goal of a second mid-stage trial, sending its shares down as much as 51 percent in extended trade. MediciNova, which is testing MN-221 as a
MediciNova Reports Results of a Phase 2b Clinical Trial of MN-221 in Asthma MarketWatch (press release)
MediciNova (MNOV) Says Results of Phase 2B Trial of MN-221 Didn't Meet Primary StreetInsider.com (subscription)

all 11 news articles »

View full post on asthma – Google News